Kenneth Pienta - 20 Dec 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Medical Officer
Signature
/s/ Kenneth Pienta by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
20 Dec 2021
Net transactions value
$0
Form type
4
Filing time
21 Dec 2021, 15:05:58 UTC
Next filing
29 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +80,000 $0.000000 80,000 20 Dec 2021 Common Stock 80,000 $11.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in four equal semi-annual installments beginning June 20, 2022.